These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 34522991)

  • 1. Myeloperoxidase immunohistochemical staining can identify glomerular endothelial cell injury in dense deposit disease.
    Blatt NB; Kumar T; Wickman LT; Kanaan HD; Chang A; Zhang PL
    Pediatr Nephrol; 2021 Dec; 36(12):4003-4007. PubMed ID: 34522991
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Apolipoprotein E is enriched in dense deposits and is a marker for dense deposit disease in C3 glomerulopathy.
    Madden B; Singh RD; Haas M; Palma LMP; Sharma A; Vargas MJ; Gross L; Negron V; Nate T; Charlesworth MC; Theis JD; Nasr SH; Nath KA; Fervenza FC; Sethi S
    Kidney Int; 2024 May; 105(5):1077-1087. PubMed ID: 38447879
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Morphofunctional Effects of C5 Convertase Blockade in Immune Complex-Mediated Membranoproliferative Glomerulonephritis: Report of Two Cases with Evidence of Terminal Complement Activation.
    Carrara C; Podestà MA; Abbate M; Rizzo P; Piras R; Alberti M; Daina E; Ruggenenti P; Remuzzi G;
    Nephron; 2020; 144(4):195-203. PubMed ID: 32050203
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pathology after eculizumab in dense deposit disease and C3 GN.
    Herlitz LC; Bomback AS; Markowitz GS; Stokes MB; Smith RN; Colvin RB; Appel GB; D'Agati VD
    J Am Soc Nephrol; 2012 Jul; 23(7):1229-37. PubMed ID: 22677550
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment-resistant nephrotic syndrome in dense deposit disease: complement-mediated glomerular capillary wall injury?
    Duineveld C; Steenbergen EJ; Bomback AS; van de Kar NCAJ; Wetzels JFM
    Pediatr Nephrol; 2020 Sep; 35(9):1791-1795. PubMed ID: 32447506
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Kidney Transplantation in C3 Glomerulopathy: A Case Series.
    Regunathan-Shenk R; Avasare RS; Ahn W; Canetta PA; Cohen DJ; Appel GB; Bomback AS
    Am J Kidney Dis; 2019 Mar; 73(3):316-323. PubMed ID: 30413277
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Eculizumab for treatment of rapidly progressive C3 glomerulopathy.
    Le Quintrec M; Lionet A; Kandel C; Bourdon F; Gnemmi V; Colombat M; Goujon JM; Frémeaux-Bacchi V; Fakhouri F
    Am J Kidney Dis; 2015 Mar; 65(3):484-9. PubMed ID: 25530108
    [TBL] [Abstract][Full Text] [Related]  

  • 8. C3 Glomerulopathy.
    Riedl M; Thorner P; Licht C
    Pediatr Nephrol; 2017 Jan; 32(1):43-57. PubMed ID: 27056062
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterization of C3 in C3 glomerulopathy.
    Sethi S; Vrana JA; Fervenza FC; Theis JD; Sethi A; Kurtin PJ; Zhang Y; Smith RJH
    Nephrol Dial Transplant; 2017 Mar; 32(3):459-465. PubMed ID: 27507892
    [TBL] [Abstract][Full Text] [Related]  

  • 10. C3 glomerulopathy and current dilemmas.
    Ito N; Ohashi R; Nagata M
    Clin Exp Nephrol; 2017 Aug; 21(4):541-551. PubMed ID: 27878657
    [TBL] [Abstract][Full Text] [Related]  

  • 11. C3 glomerulopathy in a patient with a history of post-infectious glomerulonephritis.
    Nnadi N; Hendricks AR; Torrealba J; Drake KA; Gattineni J
    Pediatr Nephrol; 2024 Mar; 39(3):745-748. PubMed ID: 37874356
    [TBL] [Abstract][Full Text] [Related]  

  • 12. C3 glomerulonephritis with a severe crescentic phenotype.
    Ravindran A; Fervenza FC; Smith RJH; Sethi S
    Pediatr Nephrol; 2017 Sep; 32(9):1625-1633. PubMed ID: 28593446
    [TBL] [Abstract][Full Text] [Related]  

  • 13. C4 Glomerulopathy: A Disease Entity Associated With C4d Deposition.
    Sethi S; Quint PS; O'Seaghdha CM; Fervenza FC; Bijol V; Dorman A; Dasari S; Smith RJ; Kurtin PJ; Rennke HG
    Am J Kidney Dis; 2016 Jun; 67(6):949-53. PubMed ID: 26896898
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discontinuation of dialysis with eculizumab therapy in a pediatric patient with dense deposit disease.
    Tran CL; Sethi S; Murray D; Cramer CH; Sas DJ; Willrich M; Smith RJ; Fervenza FC
    Pediatr Nephrol; 2016 Apr; 31(4):683-7. PubMed ID: 26759144
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Proliferative C4 Dense Deposit Disease, Acute Thrombotic Microangiopathy, a Monoclonal Gammopathy, and Acute Kidney Failure.
    Ali A; Schlanger L; Nasr SH; Sethi S; Gorbatkin SM
    Am J Kidney Dis; 2016 Mar; 67(3):479-82. PubMed ID: 26704376
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of C4d as a diagnostic tool to classify membranoproliferative glomerulonephritis.
    Gupta N; Wakefield DN; Clapp WL; Garin EH
    Nefrologia; 2017; 37(1):78-86. PubMed ID: 27595516
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Acquired and genetic complement abnormalities play a critical role in dense deposit disease and other C3 glomerulopathies.
    Servais A; Noël LH; Roumenina LT; Le Quintrec M; Ngo S; Dragon-Durey MA; Macher MA; Zuber J; Karras A; Provot F; Moulin B; Grünfeld JP; Niaudet P; Lesavre P; Frémeaux-Bacchi V
    Kidney Int; 2012 Aug; 82(4):454-64. PubMed ID: 22456601
    [TBL] [Abstract][Full Text] [Related]  

  • 18. C3 glomerulopathies. A new perspective on glomerular diseases.
    Rabasco-Ruiz C; Huerta-Arroyo A; Caro-Espada J; Gutiérrez-Martínez E; Praga-Terente M
    Nefrologia; 2013; 33(2):164-70. PubMed ID: 23511752
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of C3 glomerulopathy with complement blockers.
    Vivarelli M; Emma F
    Semin Thromb Hemost; 2014 Jun; 40(4):472-7. PubMed ID: 24799307
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Eculizumab in Pediatric Dense Deposit Disease.
    Oosterveld MJ; Garrelfs MR; Hoppe B; Florquin S; Roelofs JJ; van den Heuvel LP; Amann K; Davin JC; Bouts AH; Schriemer PJ; Groothoff JW
    Clin J Am Soc Nephrol; 2015 Oct; 10(10):1773-82. PubMed ID: 26316621
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.